We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.50 | 0.40 | 0.55 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMMTFB
Motif Bio PLC
26 August 2016
Motif Bio plc
("Motif Bio" or the "Company")
Chief Medical Officer to present at the World Anti-Microbial Resistance Congress
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that Dr. David Huang, Chief Medical Officer, will lead a panel discussion at the World Anti-Microbial Resistance Congress in Washington, USA on 9 September 2016.
The discussion is titled: 'In-licensing: Addressing the deficiencies in the original development program to develop a unique non-combination anti-infective'
For further information on the conference please see:
http://www.terrapinn.com/conference/antimicrobial-resistance-congress-usa/index.stm
For further information please contact:
Hot Features
Premium
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief
Executive Officer)
Walbrook PR Ltd. (FINANCIAL +44 (0) 20 7933 8780 or
PR & IR) motifbio@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541
893
Mike Wort Mob: +44 (0)7900 608
002
About Motif Bio
Motif Bio plc is a clinical stage biopharmaceutical company engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections which are often caused by MRSA. We are currently enrolling and dosing patients in two global Phase 3 clinical trials with an IV formulation of iclaprim, for the treatment of ABSSSI.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAAKPDDKBKBQFB
(END) Dow Jones Newswires
August 26, 2016 02:00 ET (06:00 GMT)
1 Year Motif Bio Chart |
1 Month Motif Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
